BioCentury
ARTICLE | Company News

NICE backs Xtandi for prostate cancer

October 18, 2013 12:23 AM UTC

The U.K.'s NICE issued Xtandi enzalutamide from Astellas Pharma Inc. (Tokyo:4503) to treat hormone-relapsed, metastatic prostate cancer in men whose disease has progressed on or after docetaxel therapy. The recommendation is contingent on Astellas providing Xtandi at an undisclosed discount under a patient access scheme. Comments are due Nov. 8. ...